Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979109 | 0.80 | ALDH1A1 (0.37) | ALDH1A1TP53SMN1; SMN2CA1CA2 | |
| SCHEMBL17491120 | 0.79 | CA1 (0.41) | ALDH1A1TP53SMN1; SMN2CA1CA2 | |
| SCHEMBL4132962 | 0.77 | CA1 (0.54) | CA1CA2CA9 | |
| SCHEMBL17466437 | 0.76 | CA1 (0.33) | ALDH1A1TP53SMN1; SMN2CA1CA2 | |
| SCHEMBL977331 | 0.76 | CA2 (0.34) | ALDH1A1TP53SMN1; SMN2CA1CA2 | |
| SCHEMBL19348714 | 0.76 | CA1 (0.60) | CA1CA2CA9MEN1KMT2A | |
| SCHEMBL7257180 | 0.76 | ALDH1A1 (0.35) | ALDH1A1TP53SMN1; SMN2CA1CA2 | |
| SCHEMBL22007022 | 0.75 | CA1 (0.36) | CA1CA2CA9 | |
| SCHEMBL17456472 | 0.74 | MEN1 (0.35) | ALDH1A1TP53SMN1; SMN2CA1CA2 | |
| Lithium Ion SCHEMBL17456441 | 0.74 | MEN1 (0.35) | ALDH1A1TP53SMN1; SMN2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760737-B2 | Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine | ADVERIO PHARM GmbH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-20220089554-A1 | PROCESS FOR MANUFACTURING 4-(2,2,3,3-TETRAFLUOROPROPYL)MORPHOLINE | ADVERIO PHARMA GMBH (DE) | 2022-03-24 | — | — | US | disclosed |
| CN-113272286-A | Process for preparing 4- (2,2,3, 3-tetrafluoropropyl) morpholine | 阿德弗里奥药品有限责任公司 | 2021-08-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089554-A1 | PROCESS FOR MANUFACTURING 4-(2,2,3,3-TETRAFLUOROPROPYL)MORPHOLINE | CYP4F3, CYP4F2, TNNT2 | ALDH1A1 1938/4885TP53 4143/4885SMN1; SMN2 856/4885 |
| US-11760737-B2 | Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine | CYP4F3, CYP4F2, TNNT2 | ALDH1A1 1938/4885TP53 4143/4885SMN1; SMN2 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.